Αρχειοθήκη ιστολογίου

Πέμπτη 8 Ιουνίου 2017

Novocure launches Optune, chemotherapy combo trial for glioblastoma

Novocure (NSDQ:NVCR) said today that the 1st patient was enrolled in a Phase II pilot trial evaluating Optune with bevacizumab, a chemotherapy, for patients with refractory recurrent glioblastoma. In recurrent GBM, Optune and bevacizumab are approved as monotherapies. Novocure's consortium study is slated to evaluate the efficacy and safety of the Optune-chemo combo in patients with bevacizumab-refractory recurrent GBM. Get the full story at our sister site, Drug Delivery Business News. The post Novocure launches Optune, chemotherapy combo trial for glioblastoma appeared first on MassDevice. (Source: Mass Device)

from ! Medicine by Alexandros G. Sfakianakis via alwin on Inoreader http://ift.tt/2s0QhyZ
via IFTTT

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Medicine by Alexandros G. Sfakianakis,Anapafseos 5 Agios Nikolaos 72100 Crete Greece,00302841026182,00306932607174,alsfakia@gmail.com,

Αναζήτηση αυτού του ιστολογίου

! # Ola via Alexandros G.Sfakianakis on Inoreader